Tracy McGowan, M.D.

Dr. Tracy McGowan recently retired after nearly 20 years at Johnson & Johnson (J&J), where she most recently served as the Therapeutic Area Head for Prostate Cancer. During her tenure, she led cross-functional teams responsible for the successful launch of nine new oncology therapies—three for prostate cancer and one for bladder cancer. Her leadership was instrumental in designing pivotal clinical trials, fostering collaborations with leading scientific and advocacy organizations, and building high-performing teams that earned widespread recognition through publications and presentations.

Before joining J&J, Dr. McGowan was an Associate Professor in the Divisions of Clinical Pharmacology and Nephrology at Thomas Jefferson University School of Medicine and Hospital, where she contributed to academic research and medical education.

Dr. McGowan brings a wealth of industry and academic experience to the PCEC, with a particular focus on addressing health disparities in underserved communities. Her deep understanding of barriers to cancer screening and access to clinical trials enhances the diverse expertise of the current board.